Los Angeles, CA, Sept. 11, 2025 (GLOBE NEWSWIRE) -- Immix Biopharma, Inc., a clinical-stage biopharmaceutical company focused on developing cell therapies for AL Amyloidosis and other serious diseases, announced that Nancy T. Chang has joined its Board of Directors. Dr. Chang, a former CEO of Tanox, Inc., brings extensive experience in biotechnology, having led the development and commercialization of several FDA-approved drugs. Her appointment coincides with her investment as a founding member of Goose Capital.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Immix Biopharma Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9527160-en) on September 11, 2025, and is solely responsible for the information contained therein.